Figure 1

Differentiated access to RT-PCR testing in patients who answered the COVIDOM survey (N = 31,323). (a) Description of the investigations in the COVIDOM cohort combining the survey and the EDS database: 54,358 patients are included in the web-application for daily monitoring, among which 31,323 answered the complete survey. (b) Description of repeated RT-PCR testing for patients included in the Corona OMOP database (N = 6621). Patients benefited from 1 to 10 RT-PCR tests each. Median time between RT-PCR1 and RT-PCR2 was 8 days, RT-PCR1 and RT-PCR3: 13 days, RT-PCR1 and RT-PCR4: 15 days, RT-PCR1 and RT-PCR5: 21 days. (c) Access to RT-PCR testing in patients who answered the COVIDOM survey, as a function of various patient characteristics. The size of the black bar indicates the proportion that has been tested of a given group.. The population is stratified based on demographic characteristics, tobacco usage, comorbidities (“any” includes any of the following or hypertension, chronic kidney disease, cancer under treatment or other as indicated by the patient, “respiratory” indicates asthma or COPD, “cardio-vascular” indicates heart failure or coronary disease, obesity a BMI above 30), symptoms experienced at some point of the disease (“cardiopulmonary” indicates breathlessness associated to chest oppression or chest pain), need for admission in hospital before or after inclusion in COVIDOM. The right column indicates the odd-ratios of being tested in each group, compared to the complementary group. We test whether these odds ratios significantly differ from 1 using a Wald test. Table S1 provides all numerical data.